Edmonton, Canada (ots/PRNewswire) - - Trades on Toronto Stock Exchange - (TSX:ISA) Isotechnika Inc. announced today that the Company received approval from the Polish Competent Authority for participation in the ongoing Phase 3 European/Canadian clinical trial. This trial investigates the use of ISA247 ...
Chicago (ots/PRNewswire) - - Oral Xeloda(R) Combination Effective and Time-Saving Data presented today at the American Society of Clinical Oncology Annual Meeting (ASCO) in Chicago showed that not only is XELOX as effective as intravenous (i.v.) drug regimens, but that colorectal cancer patients who ...
Alderley Park, England (ots/PRNewswire) - - FOR NON-US/NON-UK MEDICAL MEDIA ONLY ALDERLEY PARK, England, June 4 /PRNewswire/ -- AstraZeneca (LSE: AZN; NYSE: AZN) today announced details of two new investigational cancer therapies at the American Society of Clinical Oncology (ASCO) meeting. AZD2281 (KU-0059436) is a small molecule inhibitor of ...
Chicago (ots/PRNewswire) - - Study Highlights Quality-of-Life Data ALIMTA(R) (pemetrexed for injection) showed additional utility in the treatment of the most diagnosed type of cancer(i), according to data presented today at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO). ...
Chicago, Illinois (ots/PRNewswire) - - One Year Results From the ARIBON Study Presented at ASCO 2007 Bondronat(R) (ibandronic acid) has been shown to prevent bone loss caused by anastrozole in post-menopausal women given adjuvant therapy for early breast cancer according to results from the ARIBON ...
Chicago (ots/PRNewswire) - - Five Phase III Early-Stage Breast Cancer Studies Underway With GEMZAR GEMZAR(R) (gemcitabine HC1 for injection), approved in combination with paclitaxel (Taxol(R)) in the first-line, post-surgical treatment of metastatic breast cancer, was the subject of a study ...
Chicago (ots/PRNewswire) - - Patients Have a Chance to Live Almost Twice as Long Without Their Disease Returning Adding Avastin (bevacizumab) to interferon offers patients with advanced renal cell cancer the chance to live twice as long without their disease advancing ("progression free survival") compared with interferon alone. This is according to results ...
Chicago, Illinois (ots/PRNewswire) - - Only First-line Treatment to Demonstrate Extended Survival in Over a Decade Avastin (bevacizumab), significantly improves the time patients with advanced non-small cell lung cancer (NSCLC) live without their disease advancing ("progression free survival") when added to cisplatin/gemcitabine chemotherapy, compared with ...
Indianapolis (ots/PRNewswire) - - Luminous Award recognizes outstanding cancer journalism from outlets around the world Following the success of the inaugural Luminous Award in 2006, Lilly Oncology announced today the call for entries to Luminous 2007. The Luminous Award was created by Lilly to honour journalism that serves readers and viewers by providing responsible, accurate and timely information on ...
Collegeville, Pennsylvania (ots/PRNewswire) - - TORISEL Is Proven to Extend Overall Survival for People with Advanced Renal Cell Carcinoma - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the U.S. Food and Drug Administration (FDA) has approved TORISEL(TM) (temsirolimus) for ...
Irvine, California (ots/PRNewswire) - - FDA Reinitiates 510(k) Review IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced that it recently received a positive response from the Center for Biologics Evaluation and Research (CBER) and the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA), confirming that IsoTis' Accell family of demineralized ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced it has secured a $20 Million credit facility with Merrill Lynch Capital, a division of Merrill Lynch Business Financial Services Inc., and Silicon Valley Bank. The three-year $20 million credit facility has two components: a $10 million term loan and a ...
Basel, Switzerland (ots/PRNewswire) - Roche announced today that it has received a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) recommending a marketing authorisation be granted for MIRCERA for the treatment of anaemia associated with chronic kidney disease. MIRCERA is ...
Bethesda, Maryland, and Roskilde, Denmark (ots/PRNewswire) - Micromet, Inc. (Nasdaq: MITI) and Nycomed today announced an agreement under which the two companies will collaborate on the development of anti-GM-CSF antibodies that may be useful for the treatment of inflammatory and autoimmune diseases. The lead ...
Milan, Italy and Stockholm, Sweden (ots/PRNewswire) - - Three-Quarters of Women Were Not Told Their Risk of Recurrence - Older, Less Educated Women or Those Without Internet Access are Particularly Uninvolved and Uninformed - New Tools, Better Communication Between Health Care Professionals and ...
Boehringer Ingelheim GmbH and Eli Lilly and Company
San Diego (ots/PRNewswire) - Depression, well known to reduce workplace productivity, causes significantly greater productivity declines when accompanied by common co-occurring conditions such as fatigue, sleep problems or anxiety, according to a large new study presented today at the American Psychiatric Association's 160th Annual Meeting in San Diego.(1) The ...
RUEIL- MALMAISON, France, May 23 (ots/PRNewswire) - - Innovative, First-in-Class Medicine Provides New Option for Europeans With Debilitating Disease Bristol-Myers Squibb (NYSE: BMY) announced today the European Commission has granted an approval for ORENCIA(R) (abatacept) for the treatment of rheumatoid ...
Oss and Eindhoven, The Netherlands (ots/PRNewswire) - N.V. Organon, the human health care business unit of Akzo Nobel, and Royal Philips Electronics announced today that they will join forces in the development of new drugs and therapies for mental disorders and cancer. With the help of biomarkers (specific molecules or cells which can be measured as an indicator of ...
Indianapolis (ots/PRNewswire) - - 37 Thoracic Cancer Studies; 11 Breast Cancer Studies; 9 Targeted Agent Studies Lilly Oncology will unveil 76 studies at the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Ill. from June 1-5, 2007. The company will present important data on GEMZAR(R) (gemcitabine HCl for injection), ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT), the orthobiologics company, today announced that it has expanded its existing private label agreement with AlloSource. AlloSource is IsoTis' primary supply partner and one of the nation's largest non-profit providers of bone and soft ...
Paris (ots/PRNewswire) - - Data From Multicentre Registry Show Significant Benefit With Closed-Cell Stents in the Treatment of Carotid Artery Stenosis Boston Scientific Corporation (NYSE: BSX) welcomed results from a large independent registry confirming the benefit of closed-cell stents in patients with carotid artery stenosis. The results, published in the ...
Brussels (ots/PRNewswire) - A unique joint declaration by AIDS activists, doctors, researchers, pharmaceutical companies and members of regulatory agencies has been issued demanding the urgent development of better treatment options for people co-infected with the HIV and hepatitis C (HCV) viruses. The ...
Vienna, Austria (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced new data that showed that, in moderate to severe plaque psoriasis patients, ENBREL(R) (etanercept) reduced the severity of nail psoriasis by more than 28 percent at 12 weeks and reduced the signs and ...
Paris (ots/PRNewswire) - - Lovenox(R) is the Low-Molecular Weight Heparin, Approved in the United States for the Broadest Range of Indications Sanofi-aventis announced today that the Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the anticoagulant Lovenox(R) ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc (NASDAQ: ISOT), an orthobiologics company, today reported results for the first quarter ended March 31, 2007. Revenue Analysis Revenue was US$10.0 million for the first quarter of 2007, representing a 2% increase over revenue of US$9.8 million for the first quarter of 2006. IsoTis' chief distribution channels are its U.S. network of independent distributor ...
Tokyo (ots/PRNewswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito) announced that the company has signed on May 14, 2007 (the U.S. Eastern Time) the exclusive agreement with Solstice Neurosciences, Inc. (Headquarters: Pennsylvania, U.S., President & CEO: Shawn Patrick O'Brien) for NeuroBloc(R) , an injectable form of botulinum toxin ...
Collegeville, Pennsylvania and Tarrytown, New York (ots/PRNewswire) - - Application for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that Wyeth has ...
Pittsburgh (ots/PRNewswire) - - Combination Creates a World Class Global Generics Leader - - Significant Scale and Breadth Will Drive Major Operating Efficiencies - - Highly Complementary Transaction Further Strengthens Mylan's Product Portfolio - - Accelerates Mylan's Revenue and Earnings Growth - - Anticipated to be Cash EPS(1) Neutral in 2nd Full Year - Mylan Laboratories Inc. (NYSE: MYL) ...
Boxmeer, The Netherlands (ots/PRNewswire) - Intervet, a leading animal health company, received approval for its bird flu (avian influenza) vaccine Nobilis(R) Influenza H7N1. As a result, Europe now has a licensed vaccine to protect birds against the H7 field strain. Last year the European Commission approved Nobilis(R) Influenza H5N2. With the registration Intervet confirms its leading position in AI vaccines ...
Ingelheim, Germany (ots/PRNewswire) - - Trial to Compare Efficacy and Safety of Viramune(R) (Nevirapine) Versus Atazanavir/Ritonavir in Treatment-Naive Patients Boehringer Ingelheim GmbH announced today that it has initiated and begun enrollment of patients in the ArTEN trial, which will compare the efficacy and safety of Viramune(R) (nevirapine), ...